Vistagen Therapeutics Inc (VTGN)

$0.61 -0.03 (-5.18%)
Market Cap 24.17M
Revenue (ttm) 490,000.00
Net Income (ttm) -51.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,493.88%
Debt to Equity Ratio 0.00
Volume 436,800
Avg Vol 937,854
Day's Range N/A - N/A
Shares Out 39.62M
Stochastic %K 46%
Beta 0.29
Analysts Hold
Price Target $0.97

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
MaskMaker
MaskMaker Mar. 21 at 6:55 AM
$NXL $GRRR $VTGN $AVXL $SAVA
0 · Reply
MaskMaker
MaskMaker Mar. 20 at 8:53 PM
$APCX $IGC $MPU $NXL $VTGN
0 · Reply
mb0157
mb0157 Mar. 20 at 6:10 PM
$VTGN
1 · Reply
marketCaptain
marketCaptain Mar. 19 at 3:30 PM
$VTGN Looks like The cat is out of the box. Some ppl are connecting the dots regarding The board
2 · Reply
BioBum
BioBum Mar. 19 at 9:49 AM
$VTGN you know they already peaked at the data. Board members leaving. Cant even see this through for a few more months. It’s a cake board job, and you leave right before a pivotal readout
1 · Reply
MaskMaker
MaskMaker Mar. 19 at 9:33 AM
$APCX $NXL $MPU $VTGN $IGC Alzheimer’s Disease Prevention starts Here
0 · Reply
mb0157
mb0157 Mar. 18 at 9:38 PM
$VTGN another board resignation. And diamond sponsor at ADAA April 9. Resignation effective April 1. Folks. Writing on wall. Making room for new big time transactional board aka big pharma
3 · Reply
Reatavegas
Reatavegas Mar. 18 at 9:35 PM
$VTGN chairman...gone. please appoint someone not on board. thank you
0 · Reply
Biggie_Small_Fries
Biggie_Small_Fries Mar. 18 at 7:25 PM
$VTGN Add this to the ph94b maybe the results will pass !
0 · Reply
MaskMaker
MaskMaker Mar. 18 at 6:04 PM
$NXL People here are spreading False information, while I keep adding everyday. $VTGN $GRRR $SAVA
1 · Reply
Latest News on VTGN
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline

Mar 11, 2026, 4:36 PM EDT - 10 days ago

Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline

Vistagen to Participate in Upcoming Investor Conferences

Mar 3, 2026, 8:30 AM EST - 18 days ago

Vistagen to Participate in Upcoming Investor Conferences

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Feb 25, 2026, 8:30 AM EST - 24 days ago

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Feb 12, 2026, 4:30 PM EST - 5 weeks ago

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Feb 9, 2026, 5:21 PM EST - 5 weeks ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Feb 6, 2026, 9:52 AM EST - 6 weeks ago

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Feb 4, 2026, 8:30 AM EST - 6 weeks ago

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Jan 29, 2026, 8:24 AM EST - 7 weeks ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 22, 2026, 10:45 AM EST - 2 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jan 16, 2026, 5:06 PM EST - 2 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Dec 17, 2025, 12:42 PM EST - 3 months ago

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 17, 2025, 8:30 AM EST - 3 months ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 3 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 26, 2025, 8:30 AM EST - 4 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 13, 2025, 4:30 PM EST - 4 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 10, 2025, 8:30 AM EST - 4 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 4 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Nov 3, 2025, 8:30 AM EST - 4 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 5 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 5 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 8:30 AM EDT - 6 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Aug 7, 2025, 4:30 PM EDT - 8 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 31, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jul 15, 2025, 8:30 AM EDT - 8 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 25, 2025, 8:30 AM EDT - 9 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:30 PM EDT - 9 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 12, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Jun 2, 2025, 8:30 AM EDT - 10 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 20, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 13, 2025, 4:30 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 6, 2025, 8:30 AM EST - 1 year ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Feb 5, 2025, 8:30 AM EST - 1 year ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 14, 2025, 8:30 AM EST - 1 year ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Jan 10, 2025, 8:30 AM EST - 1 year ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 7, 2024, 4:20 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

MaskMaker
MaskMaker Mar. 21 at 6:55 AM
$NXL $GRRR $VTGN $AVXL $SAVA
0 · Reply
MaskMaker
MaskMaker Mar. 20 at 8:53 PM
$APCX $IGC $MPU $NXL $VTGN
0 · Reply
mb0157
mb0157 Mar. 20 at 6:10 PM
$VTGN
1 · Reply
marketCaptain
marketCaptain Mar. 19 at 3:30 PM
$VTGN Looks like The cat is out of the box. Some ppl are connecting the dots regarding The board
2 · Reply
BioBum
BioBum Mar. 19 at 9:49 AM
$VTGN you know they already peaked at the data. Board members leaving. Cant even see this through for a few more months. It’s a cake board job, and you leave right before a pivotal readout
1 · Reply
MaskMaker
MaskMaker Mar. 19 at 9:33 AM
$APCX $NXL $MPU $VTGN $IGC Alzheimer’s Disease Prevention starts Here
0 · Reply
mb0157
mb0157 Mar. 18 at 9:38 PM
$VTGN another board resignation. And diamond sponsor at ADAA April 9. Resignation effective April 1. Folks. Writing on wall. Making room for new big time transactional board aka big pharma
3 · Reply
Reatavegas
Reatavegas Mar. 18 at 9:35 PM
$VTGN chairman...gone. please appoint someone not on board. thank you
0 · Reply
Biggie_Small_Fries
Biggie_Small_Fries Mar. 18 at 7:25 PM
$VTGN Add this to the ph94b maybe the results will pass !
0 · Reply
MaskMaker
MaskMaker Mar. 18 at 6:04 PM
$NXL People here are spreading False information, while I keep adding everyday. $VTGN $GRRR $SAVA
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 3:48 PM
$VTGN RSI: 50.97, MACD: -0.0203 Vol: 0.02, MA20: 0.60, MA50: 0.61 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MaskMaker
MaskMaker Mar. 17 at 9:52 PM
$NXL Low volume manipulation. People calling it “scam” without a hint of evidence or justification. $VTGN
0 · Reply
MaskMaker
MaskMaker Mar. 17 at 9:42 PM
$NXL $VTGN
0 · Reply
Tonyboner
Tonyboner Mar. 17 at 7:16 PM
$VTGN Expecting early fail on PH94B, every Phase 3 they have done is a Fail, I see no reason for this to be any different.
1 · Reply
BioBum
BioBum Mar. 17 at 5:25 PM
$VTGN what’s crazy is that this could do $12 on a palisade 4 pass 😆
2 · Reply
AStrokeOfLuck
AStrokeOfLuck Mar. 17 at 4:43 PM
$VTGN if they can straighten the ship and get it through...maybe
0 · Reply
mark31
mark31 Mar. 17 at 4:33 PM
$VTGN fire side chat was good info moving up now
0 · Reply
nicho208
nicho208 Mar. 17 at 4:29 PM
$VTGN
0 · Reply
DAP89
DAP89 Mar. 17 at 4:24 PM
$VTGN 🤫
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Mar. 17 at 1:41 PM
$VTGN March 2026 corporate presentation pretty thorough https://www.vistagen.com/static-files/0c45ce9b-da51-4a35-8a3b-ec2d06549a52
1 · Reply
mark88arg
mark88arg Mar. 17 at 1:19 PM
$VTGN i cant believe how this managment still in this company ..
0 · Reply
ZOMEDICAisHeatingUP
ZOMEDICAisHeatingUP Mar. 16 at 11:30 PM
$VTGN A gentle reminder that CEO Shawn Singh is a POS Sacammer.
0 · Reply